Comparative Gene Expression Profiling of Benign and Malignant Lesions Reveals Candidate Therapeutic Compounds for Leiomyosarcoma

Table 1

Mechanisms of action and cmap enrichment scores for drugs tested in LMS cell lines.

Drug name	Mechanism of action	Clinical use	LMS I cmap score	LMS II cmap score	LMS III cmap score
2-Deoxy-d-glucose	Glycolysis inhibitor	Epilepsy, optical imaging agent	0.952	0.874	0.514
MG-132	Proteasome inhibitor, JNK1 activator, and NF-𝜅B inhibitor	None	−0.535	0.792	−0.981
Metformin HCl	Gluconeogenesis inhibitor, AMPK activator	Type II diabetes, gestational diabetes, and polycystic ovary syndrome	−0.217	0.147	0.315
LY-294002	PI3K inhibitor	None	−0.157	−0.085	−0.3
Sirolimus	mTOR inhibitor	Organ transplant rejection	0.135	−0.109	−0.155
Doxorubicin	Topoisomerase II inhibitor	Solid cancers, hematological cancers	−0.536	−0.724	0.409
Gefitinib	EGFR inhibitor	Nonsmall cell lung cancer	−0.941	−0.83	.736
Tyrphostin AG-825	EGFR inhibitor	None	−0.982	−0.893	0.905
6-Thioguanine	Antimetabolite	Acute leukemia, chronic myeloid leukemia	0.564	−0.913	0.866
Cantharidin	Protein phosphatase inhibitor	None	−0.977	−0.931	−0.98
Oxamic acid	Lactate dehydrogenase inhibitor	None	−0.867	−0.964	0.893